Perbedaan Organon Pharma Indonesia Tbk. dan Solusi Bangun Indonesia Tbk.: Organon Pharma Indonesia Tbk. diperdagangkan di Rp29.000 (kapitalisasi pasar 104,4 M), sedangkan Solusi Bangun Indonesia Tbk. diperdagangkan di Rp775 (kapitalisasi pasar 6,99 T). Perbedaan utamanya: Solusi Bangun Indonesia Tbk. jauh lebih besar — sekitar 67× kapitalisasi pasar Organon Pharma Indonesia Tbk.. Mana yang lebih baik tergantung tujuan investasimu.
| SCPI | SMCB | |
|---|---|---|
Kapitalisasi Pasar | 104,4 M | 6,99 T |
Imbal hasil berjalan pada periode standar
Berita terbaru kedua aset
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Selengkapnya di halaman SCPI →PT Holcim Indonesia Tbk (the Company) was originally a joint venture between a subsidiary of Kaiser Cement and Gypsum Corp. and PT Semen Gresik. Founded in 1971, the company owns a factory in Narogong, West Java, with an annual capacity of 3 million tons. The Company changed its foreign capital investment status (PMA) to domestic capital investment (PMDN) based on the approval from Chairman of Capital Investment Coordinating Board No. 17/V/1988 dated November 19, 1988. Effective January 1, 2006, the Company changed its name from PT Semen Cibinong Tbk. to PT Holcim Indonesia Tbk.
Selengkapnya di halaman SMCB →